MedPage Today on MSN

Non-ablative treatment for BPH/LUTS achieves rapid, sustained improvements

Results with Optilume consistent in clinical trials and real world, regardless of prostate ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...
Pharmabiz

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...
Medscape

This Test Could Predict Who Will Experience Incontinence After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for ...
Cure Today

Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...